White House looks for path to provide experimental Ebola drugs to infected patients

Drugmakers who sell unapproved drugs are generally setting themselves up for big penalties from federal authorities. The Obama administration, under mounting pressure, intends to craft a policy for using experimental drugs to treat the Ebola virus, Reuters reports. The White House Friday said it is setting up a working group to consider the use of drugs on the hundreds patients in Africa infected by the deadly virus, which has killed nearly 1,000 so far. The FDA already allowed an experimental drug from California-based Mapp Biopharmaceutical to be used to treat two U.S. aid workers who became infected. But any accelerated use of the drugs poses potential threats to patients and the drugmakers, so a policy and pathway to use will have to be designed carefully. Story | More

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…